Comprehensive characterization of protein-protein interaction network perturbations by human disease mutations

Technological and computational advances in genomics and interactomics have made it possible to identify rapidly how disease mutations perturb interaction networks within human cells. In this study, we investigate at large-scale the effects of network perturbations caused by disease mutations within the human three-dimensional (3D), structurally-resolved macromolecular interactome. We show that disease-associated germline mutations are significantly enriched in sequences encoding protein-protein interfaces compared to mutations identified in healthy subjects from the 1000 Genomes and ExAC projects; these interface mutations correspond to protein-protein interaction (PPI)-perturbing alleles including p.Ser127Arg in PCSK9 at the PCSK9-LDLR interface. In addition, somatic missense mutations are significantly enriched in PPI interfaces compared to non-interfaces in 10,861 human exomes across 33 cancer subtypes/types from The Cancer Genome Atlas. Using a binomial statistical model, we computationally identified 470 PPIs harboring a statistically significant excess number of missense mutations at protein-protein interfaces (termed putative oncoPPIs) in pan-cancer analysis. We demonstrate that the oncoPPIs, including histone H4 complex in individual cancer types, are highly correlated with patient survival and drug resistance/sensitivity in human cancer cell lines and patient-derived xenografts. We experimentally validate the network effects of 13 oncoPPIs using a systematic binary interaction assay. We further showed that ALOX5 p.Met146Lys at the ALOX5-MAD1L1 interface and RXRA p.Ser427Phe at the RXRA-PPARG interface promote significant tumor cell growth using cell line-based functional assays, providing a functional proof-of-concept. In summary, if broadly applied, this human 3D interactome network analysis offers a powerful tool for prioritizing alleles with mutations altering PPIs that may contribute to the pathobiology of human diseases, and may offer disease-specific targets for genotype-informed therapeutic discovery.

[1]  K. Roeder,et al.  An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders , 2018, Nature Genetics.

[2]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[3]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[4]  Carl W. Miller,et al.  Mutations in the mitotic check point gene, MAD1L1, in human cancers , 2001, Oncogene.

[5]  W. Chung,et al.  PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. , 2017, Circulation research.

[6]  István A. Kovács,et al.  Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders , 2015, Cell.

[7]  P. Stenson,et al.  The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies , 2017, Human Genetics.

[8]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[9]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[10]  Albert-László Barabási,et al.  Network-based approach to prediction and population-based validation of in silico drug repurposing , 2018, Nature Communications.

[11]  Y. Peterson,et al.  Suppression of GNAI2 message in ovarian cancer , 2014, Journal of Ovarian Research.

[12]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[13]  Jianjun Chen,et al.  ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia , 2017, Scientific Reports.

[14]  Maitreya J. Dunham,et al.  Variant Interpretation: Functional Assays to the Rescue. , 2017, American journal of human genetics.

[15]  Gustavo F. Bayón,et al.  Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment , 2019, Nucleic acids research.

[16]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[17]  S. Cai,et al.  Loss of ARHGDIA expression is associated with poor prognosis in HCC and promotes invasion and metastasis of HCC cells. , 2014, International journal of oncology.

[18]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[19]  David S. Goodsell,et al.  The RCSB protein data bank: integrative view of protein, gene and 3D structural information , 2016, Nucleic Acids Res..

[20]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[21]  R. Evans,et al.  Nuclear Receptors, RXR, and the Big Bang , 2014, Cell.

[22]  David L. Masica,et al.  Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure. , 2016, Cancer research.

[23]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[24]  R. Aebersold,et al.  On the Dependency of Cellular Protein Levels on mRNA Abundance , 2016, Cell.

[25]  Shuying Sun,et al.  SRSF1-Regulated Alternative Splicing in Breast Cancer. , 2015, Molecular cell.

[26]  G. Mills,et al.  Functional variomics and network perturbation: connecting genotype to phenotype in cancer , 2017, Nature Reviews Genetics.

[27]  Zhiping Weng,et al.  ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers , 2014, Bioinform..

[28]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[29]  Huang Gao,et al.  Database resources of the National Center for Biotechnology Information , 2015, Nucleic Acids Res..

[30]  A. Shoushtari,et al.  GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma , 2018, Cell reports.

[31]  B. Zhou,et al.  The Role of Snail in EMT and Tumorigenesis. , 2013, Current cancer drug targets.

[32]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[33]  Daiqing Liao,et al.  DAXX in cancer: phenomena, processes, mechanisms and regulation , 2019, Nucleic acids research.

[34]  W. Sellers,et al.  Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors , 2017, Clinical Cancer Research.

[35]  Hongxia Zhu,et al.  Downregulation of ARHGDIA contributes to human glioma progression through activation of Rho GTPase signaling pathway , 2016, Tumor Biology.

[36]  O. Nureki,et al.  Variegated RHOA mutations in adult T-cell leukemia/lymphoma. , 2016, Blood.

[37]  R. Dummer,et al.  Development of encorafenib for BRAF-mutated advanced melanoma , 2017, Current opinion in oncology.

[38]  The Icgctcga Pan-Cancer Analysis of Whole Genomes Consortium.  Pan-cancer analysis of whole genomes , 2020 .

[39]  Julio Saez-Rodriguez,et al.  Abstract A44: A landscape of pharmacogenomic interactions in cancer , 2017 .

[40]  Michael T. Zimmermann,et al.  Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy , 2018, Acta Neuropathologica Communications.

[41]  P. Aloy,et al.  Interactome3D: adding structural details to protein networks , 2013, Nature Methods.

[42]  Li Ding,et al.  Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.

[43]  Sean D. Taverna,et al.  Selective Inhibition of p300 HAT Blocks Cell Cycle Progression, Induces Cellular Senescence and Inhibits the DNA Damage Response in Melanoma Cells , 2013, The Journal of investigative dermatology.

[44]  P. Knoepfler,et al.  Histone H3.3 mutations: a variant path to cancer. , 2013, Cancer cell.

[45]  R. Cummings,et al.  Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of one figure. Published, JLR Papers in Press, March 19, 2008. , 2008, Journal of Lipid Research.

[46]  Patrick Aloy,et al.  A reference map of the human binary protein interactome , 2020, Nature.

[47]  M. Vidal,et al.  A genome-wide positioning systems network algorithm for in silico drug repurposing , 2019, Nature Communications.

[48]  Allison P. Heath,et al.  Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.

[49]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[50]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[51]  Asher Mullard.  Nine paths to PCSK9 inhibition , 2017, Nature Reviews Drug Discovery.

[52]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[53]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[54]  Ken Chen,et al.  Systematic Functional Annotation of Somatic Mutations in Cancer. , 2018, Cancer cell.

[55]  Leng Han,et al.  The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. , 2015, Cancer cell.

[56]  Joaquín Dopazo,et al.  A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces , 2015, PLoS Comput. Biol..

[57]  J. Sutcliffe,et al.  A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data , 2019, Nature Neuroscience.

[58]  C. Sander,et al.  3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.

[59]  Haiyuan Yu,et al.  Interactome INSIDER: a structural interactome browser for genomic studies , 2017, Nature Methods.

[60]  Peter K. Sorger,et al.  BIOPHYSICAL PREDICTION OF PROTEIN-PEPTIDE INTERACTIONS AND SIGNALING NETWORKS USING MACHINE LEARNING , 2019, Nature Methods.

[61]  Sara Reardon,et al.  Giant study poses DNA data-sharing dilemma , 2015, Nature.

[62]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[63]  Atul J. Butte,et al.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health , 2018, Pharmacological Reviews.

[64]  M. Bronstein,et al.  Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning , 2019, Nature Methods.

[65]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[66]  James A Perry,et al.  Impact of rare and common genetic variants on diabetes diagnosis by hemoglobin A1c in multi-ancestry cohorts: The Trans-Omics for Precision Medicine Program , 2019, bioRxiv.

[67]  Sun-Mi Park,et al.  Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis , 2011, Clinical Cancer Research.

[68]  Chiraag D. Kapadia,et al.  Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation , 2017, eLife.

[69]  Sriram Krishnamoorthy,et al.  Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.

[70]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .